VJHemOnc is committed to improving our service to you

IMW 2019 | RVD/KRD: 3 drug combinations as the standard frontline induction

VJHemOnc is committed to improving our service to you

Paul Richardson

Dr Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, highlights the superiority of 3 drug platforms and touches on why he believes there is value in saving the most effective drugs to be used after relapse. This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter